News & Updates

A new medication has been approved for the treatment of insomnia. Lemborexant (Dayvigo™, Eisai), is a hypnotic agent belonging to the class of drugs known as dual orexin receptor antagonists (DORAs).

Pregnant women with obsessive–compulsive disorder (OCD) are at higher risk of adverse pregnancy, delivery, and neonatal outcomes, including gestational diabetes, pre-eclampsia, caesarean delivery, preterm birth, neonatal respiratory distress, neonatal infections, and major congenital malformations, among others, as reported in a study.

Adolescents with juvenile idiopathic arthritis (JIA) remain vulnerable to symptoms of depression and anxiety, particularly panic, according to a study, noting the ongoing need for mental health screening protocols and services in this population.

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.

People with social anxiety disorder (SAD) may benefit from gaze-contingent music reward therapy (GC-MRT), an eye-tracking-based attention bias modification treatment, which has been shown to reduce SAD symptoms in a recent study.